Stenabolic (SR9009): A Tracking Guide for a REV-ERB Exercise Mimetic
A harm-reduction look at SR9009, its exercise-mimetic claims, and the poor oral bioavailability that undercuts most real-world use.
At a glance
- What it is
- REV-ERB agonist exercise mimetic
- Route
- Oral (poorly absorbed)
- Frequency
- Multiple times daily
- Typical cycle
- 4-8 weeks
- First effects
- Uncertain
Best for
SR9009, sold as stenabolic, is a REV-ERB agonist often described as an exercise mimetic - a compound proposed to reproduce some metabolic effects of exercise by acting on circadian and metabolic pathways. It is not a SARM and does not touch the androgen receptor.
The single most important practical fact comes first: SR9009 has very poor oral bioavailability. The animal research it is based on used injection, and oral dosing in humans is thought to result in minimal systemic exposure. This means much of the marketing may not translate to real effects when taken as a pill. This is an educational tracking guide, not a recommendation, and not medical advice.
What it is
- A synthetic REV-ERB agonist affecting circadian and metabolic gene expression
- Promoted for endurance, fat loss, and metabolic effects from rodent studies
- Not androgenic and not hormonally suppressive on its own
What it does
- In animal models, shifted metabolism toward fat oxidation and improved endurance markers
- In humans taken orally, likely does far less because it is poorly absorbed
- Does not build muscle directly
Typical protocol shape
- Taken orally, often multiple times per day due to a short half-life
- Doses and durations commonly reported in research literature; this guide does not prescribe one
- Frequently stacked, though the absorption problem applies regardless
What to track daily
- Endurance and perceived exertion during cardio
- Bodyweight and energy
- Sleep, given the circadian mechanism
What to track weekly
- Waist and bodyweight trend
- Conditioning benchmarks
- General well-being
Bloodwork worth doing
- A baseline metabolic and lipid panel for context
Realistic expectations
- The most likely real-world outcome is little effect, because oral absorption is poor
- No approved human use and no long-term human safety data
- Product quality and dosing accuracy are major unknowns
Safety notes
The honest headline is that oral SR9009 is poorly bioavailable, so claims drawn from injected rodent studies may not apply to a human taking it by mouth. There is no long-term human safety data, and as an unregulated research chemical it carries the usual risks of mislabeling and contamination. Anyone using it should treat both its benefits and its risks as largely uncharacterized.
Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.
Atlas entry
Stenabolic (SR9009) — half-life, route and cautions
4 h · Oral